



Marksans Pharma Ltd.

National Stock Exchange of India Limited
Listing department
Exchange plaza, C-1, Block -G
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

12th February, 2016

Sub: Unaudited Financial Results for the Quarter ended on
31st December, 2015 and Limited Review Report thereon

Dear Sir,

In terms of Clause 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith kindly find Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2015 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held on 12th February, 2016 and the Limited Review Report thereon.

The Board meeting commenced at 04.15 p.m and concluded at 05.30 p.m.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed: as above

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

Tel.: 022-26200030
7208011789
Mob.: 9892640589

Office No. 620, 6th Floor, Pearl Plaza, Opp Andheri Railway Station, Near Mc Donald's, Andheri (West), Mumbai - 400 058.
E-mail : nkmittalandassociates@gmail.com / nkm@nkmittal.com / ca_mittal@rediffmail.com • Website : www.nkmittal.com

N. K. Mittal
B.Com, FCA, LLB, EMBA

Annexure V

LIMITED REVIEW REPORT FOR THE QUARTER ENDED 31.12.2015

Review Report to The Board of Directors, Marksans Pharma Ltd.

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 31st December, 2015. This statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES
Chartered Accountants


N.K.MITTAL
(Proprietor)
M.No.46785
Place: Mumbai
Date: 12.02.2016



MARKSANS PHARMA LIMITED

Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Ostiwara, Andheri (West), Mumbai-400053 (CIN: L24110MH1992PLC066364)

Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: info@marksanspharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2015

Sr. No.	PARTICULARS	STANDALONE					CONSOLIDATED				
		3 MONTHS ENDED			9 MONTHS ENDED		3 MONTHS ENDED			9 MONTHS ENDED	
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014
1	Income	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)
a)	Net Sales/ Income from Operations (Net of excise duty)	692.95	1,170.84	1,056.40	2,887.02	3,138.55	4,055.94	2,174.07	2,555.30	2,132.94	6,830.95
b)	Other Operating Income	-	-	-	22.99	-	30.88	1.04	0.13	0.20	24.17
	Total Income from operations (net)	692.95	1,170.84	1,056.40	2,910.01	3,138.55	4,086.82	2,175.11	2,555.43	2,133.14	6,855.12
2	Expenses										
a)	Cost of Material Consumed	237.44	500.94	524.32	1,185.93	1,439.53	1,935.64	752.01	966.95	855.86	2,448.68
b)	Purchase of Stock - in- trade	30.04	52.55	48.65	142.24	200.13	232.33	338.90	365.83	374.47	1,168.05
c)	Variances in inventories or trusted goods, work-in-process and stock- in- trade	19.94	30.31	(56.30)	32.53	27.17	13.55	19.94	30.31	(56.30)	32.53
d)	Employee benefits expense	63.78	55.10	53.15	172.01	165.92	236.55	365.42	365.27	177.18	544.66
e)	Depreciation and amortisation expense	40.25	36.68	22.19	103.57	66.17	90.31	97.58	54.82	39.71	197.65
f)	Other expenses	153.98	121.86	130.24	387.74	325.56	480.46	393.02	313.26	257.32	704.56
	Total Expenses	545.43	797.44	722.25	2,024.02	2,224.48	2,988.84	1,966.87	2,096.44	1,648.24	5,709.09
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	147.52	373.40	334.15	885.99	914.07	1,097.98	208.24	458.99	484.90	1,146.03
4	Other Income	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	147.52	373.40	334.15	885.99	914.07	1,097.98	208.24	458.99	484.90	1,146.03
6	Finance cost	13.99	16.03	53.27	53.82	116.13	131.13	23.40	28.65	63.41	81.86
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	133.53	357.37	280.88	832.17	797.94	966.85	184.84	430.34	421.49	1,064.17
8	Exceptional Items	-	-	-	-	-	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	133.53	357.37	280.88	832.17	797.94	966.85	184.84	430.34	421.49	1,064.17
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	(6.35)	72.00	115.69	168.15	249.90	295.76	(1.71)	73.29	137.15	197.24
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	139.88	285.37	165.19	664.02	548.04	671.09	186.55	357.05	284.34	866.93
12	Less: Extraordinary item	-	-	-	-	-	-	-	-	-	-
13	Net Profit (Loss) for the period (11-12)	139.88	285.37	165.19	664.02	548.04	671.09	186.55	357.05	284.34	866.93
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-	7.21	8.34	7.17	24.22
16	Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)	139.88	285.37	165.19	664.02	548.04	671.09	179.34	348.71	277.17	842.71
17	Paid up Equity Share Capital (Face Value ₹1 each)	409.31	409.31	385.31	409.31	385.31	409.31	409.31	409.31	385.31	409.31
18	Reserve Excluding Revaluation Reserve	-	-	-	-	-	3,047.46	-	-	-	-
19 a)	Earnings Per Share (before extraordinary items ₹)- Basic	0.34	0.70	0.43	1.62	1.42	1.64	0.46	0.87	0.74	2.12
	Diluted	0.34	0.70	0.43	1.62	1.42	1.64	0.46	0.87	0.74	2.12
19 b)	Earnings Per Share(after extraordinary items- ₹)- Basic	0.34	0.70	0.43	1.62	1.42	1.64	0.44	0.85	0.72	2.06
	Diluted	0.34	0.70	0.43	1.62	1.42	1.64	0.44	0.85	0.72	2.06




Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.02.2016.
- 2 The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd., Marksans Pharma (U.K.) Limited and Marksans Pharma Inc. USA.
- 3 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 4 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED




MARK SALDANHA
Managing Director.

Place: Mumbai.
Date: 12.02.2016
www.marksanspharma.com